Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA

Spruce Biosciences Receives EMA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia


SAN FRANCISCO, Jan. 5, 2018 /PRNewswire/ -- Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for SPR001 for the treatment of congenital adrenal hyperplasia (CAH).

Spruce Biosciences (PRNewsfoto/Spruce Biosciences)

Earlier this month, Spruce also received orphan drug designation for SPR001 from the U.S. Food and Drug Administration (FDA). "The granting of orphan drug designation by both the EMA and FDA represents an important step forward for our lead product candidate, and underscores the high unmet medical need for developing new therapies that may benefit patients living with congenital adrenal hyperplasia," said Dr. Alexis Howerton, CEO, Spruce Biosciences.  

Spruce is currently in a Phase 2 clinical trial to assess the safety and efficacy of SPR001 in adults with classic CAH. This study is enrolling at centers across the U.S., with topline data expected in 2018. Patients interested in seeing if they may be eligible to participate can visit the clinical trial study site here

About Spruce Biosciences
Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. The Spruce team is leveraging their extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from rare endocrine diseases. Spruce's lead product candidate, SPR001, has a novel and clinically verified mechanism of action (MOA) and is currently in Phase 2 clinical trials for congenital adrenal hyperplasia, a rare disease that is screened in newborns and for which there is not yet an FDA-approved therapy. The Company is headquartered in San Francisco and closed a Series A Financing of $20 million in 2016. For more information on Spruce, please visit sprucebiosciences.com.

 

SOURCE Spruce Biosciences


These press releases may also interest you

at 15:15
Dentsu announced today the official launch of Merkury for Media, the network's latest offering within its unrivaled global data, identity, and insights platform, Merkury. The new...

at 15:11
The technology service provider market is at a crucial turning point, marked by exponential technological innovation,...

at 15:10
ServiceChannel, the leading platform for the procurement and delivery of facilities services, announced today the introduction of new solutions that empower business operators to maximize their facilities investments. The Spring 2024 Product...

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:01
G FUEL and Gearbox Entertainment Company celebrate gaming icon Duke Nukem with Ego Boost, a new zero-sugar Energy Formula now available at GFUEL.com. Fans can purchase the cherry, orange, and pomegranate flavor as a 40-serving standalone powder Tub...

at 15:00
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...



News published on and distributed by: